Information  X 
Enter a valid email address

ACTIVE BIOTECH (0GQU)

Date Time Source Announcement
05 Apr 2019 1:15 pm
GNW
Active Biotech completes sale of property
04 Apr 2019 5:00 pm
GNW
Extraordinary General Meeting of Active Biotech AB
13 Mar 2019 5:15 pm
GNW
NOTICE OF EXTRAORDINARY SHAREHOLDERS' MEETING OF ACTIVE BIOTECH AB (PUBL)
  5:00 pm
GNW
Active Biotech has entered into an agreement regarding sale of the Company's property - extraordinary general meeting on April 4, 2019
14 Feb 2019 7:30 am
GNW
Active Biotech Year-end report January - December 2018
11 Feb 2019 1:00 pm
GNW
Active Biotech's partner NeoTX enters clinical collaboration with AstraZeneca to evaluate ANYARA in combination with IMFINZI® (durvalumab) in the upcoming Phase 1b/2 study
01 Feb 2019 3:15 pm
GNW
Active Biotech has received an indicative bid for the property in Lund - the Board is positive
10 Dec 2018 11:30 am
GNW
Active Biotech provides updated information about the company's financial position
19 Nov 2018 7:30 am
GNW
Active Biotech's election committee appointed
14 Nov 2018 8:30 pm
GNW
Active Biotech AB - Interim report January - September 2018
08 Nov 2018 12:00 pm
GNW
Active Biotech: New data from the Phase 2 LEGATO-HD study will be presented at HSG 2018
13 Sep 2018 10:00 am
GNW
Active Biotech: Data from the Phase 2 LEGATO-HD study of laquinimod in Huntington's disease will be presented at "European Huntington's Disease Network (EHDN) plenary meeting 2018"
05 Sep 2018 7:30 am
GNW
Active Biotech regains global rights to development and commercialization of laquinimod
09 Aug 2018 7:30 am
GNW
Active Biotech AB - Interim Report January - June 2018
31 Jul 2018 8:15 am
GNW
Active Biotech provides update on laquinimod in Huntington's disease
31 May 2018 7:30 am
GNW
Number of shares and votes in Active Biotech
18 May 2018 7:30 am
GNW
Annual General Meeting of Active Biotech AB
17 May 2018 3:00 pm
GNW
Active Biotech AB Interim report January - March 2018
23 Apr 2018 10:30 am
GNW
Annual Report 2017 Active Biotech AB (publ)
18 Apr 2018 3:10 pm
GNW
Active Biotech: Notice of Annual General Meeting of Shareholders
12 Apr 2018 12:00 pm
GNW
Active Biotech's partner NeoTX presents new data at AACR demonstrating that ANYARA enhances the efficacy of checkpoint blockade in preclinical models of cancer
15 Feb 2018 7:40 am
GNW
NOTICE OF EXTRAORDINARY SHAREHOLDERS' MEETING
  7:30 am
GNW
Active Biotech AB Year-end report January - December 2017
20 Dec 2017 2:00 pm
GNW
Active Biotech provides updated information about the company's financial position
07 Dec 2017 6:00 pm
GNW
Active Biotech provides updated information about the company's financial position - the company currently lacks funding to ensure its operations for the coming twelve-month period
01 Dec 2017 12:00 pm
GNW
Active Biotech announce results in ARPEGGIO Phase II trial with laquinimod in Primary Progressive MS
17 Nov 2017 7:30 am
GNW
Active Biotech's election committee appointed
09 Nov 2017 7:30 am
GNW
Active Biotech AB - Interim report January - September 2017
19 Oct 2017 1:00 pm
GNW
Active Biotech's partner Teva presents new data on laquinimod for the treatment of multiple sclerosis at 7th joint ECTRIMS-ACTRIMS Meeting
10 Aug 2017 7:30 am
GNW
Active Biotech AB - Interim report January - June 2017
19 Jun 2017 2:30 pm
GNW
Helén Tuvesson new CEO of Active Biotech AB from July 1, 2017
16 Jun 2017 7:30 am
GNW
Annual General Meeting of Active Biotech AB
17 May 2017 7:30 am
GNW
Active Biotech: Notice of Annual General Meeting of Shareholders
27 Apr 2017 7:30 am
GNW
Active Biotech: Interim report January - March 2017
12 Apr 2017 12:30 pm
GNW
Active Biotech: FDA grants Orphan Drug Designation for tasquinimod for the treatment of multiple myeloma
16 Feb 2017 7:30 am
GNW
Active Biotech AB Year-end report January - December 2016
09 Jan 2017 12:00 pm
GNW
The European Patent Office grants patent for tasquinimod for treatment of multiple myeloma
30 Dec 2016 7:30 am
GNW
Number of shares and votes in Active Biotech
12 Dec 2016 4:31 pm
GNW
Active Biotech's rights issue completed
22 Nov 2016 2:05 pm
GNW
Active Biotech's election committee appointed
18 Nov 2016 2:15 pm
GNW
Prospectus relating to Active Biotech's rights issue published
11 Nov 2016 6:01 pm
GNW
Active Biotech carries out rights issue of approximately SEK 55 million
  6:00 pm
GNW
Active Biotech AB Interim report January - September 2016
26 Oct 2016 7:31 am
GNW
Active Biotech and NeoTX enter into a partnership for the development and commercialization of ANYARA for immuno-oncology
  7:25 am
GNW
Active Biotech postpone publication of the interim report
19 Sep 2016 7:30 am
GNW
Active Biotech update on laquinimod Development: The U.S, Food and Drug administration rescinds the Special Protocol Assessment for laquinimod
25 Jun 2015 1:01 pm
GNW
Teva and Active Biotech Announce Completion of Patient Enrollment in Laquinimod Phase III CONCERTO Trial
12 Jun 2015 7:30 am
GNW
Annual General Meeting of Active Biotech AB
01 Jun 2015 9:01 am
GNW
Active Biotech focuses the operations on the laquinimod project and adjusts the organization
12 May 2015 7:30 am
GNW
Notice of Annual General Meeting of Shareholders
30 Apr 2015 9:01 am
GNW
Annual Report 2014 Active Biotech AB (publ)
23 Apr 2015 7:00 pm
GNW
Teva and Active Biotech Announce First Patient Enrolled in Phase II Study Evaluating Laquinimod for Primary Progressive MS
  7:31 am
GNW
Active Biotech AB Interim report January - March 2015
16 Apr 2015 6:02 am
GNW
Active Biotech and Ipsen announce their decision to discontinue the development of tasquinimod in prostate cancer
11 Feb 2015 7:30 am
GNW
Active Biotech AB Year-end report January - December 2014
30 Jan 2015 7:30 am
GNW
Number of shares and votes in Active Biotech
12 Jan 2015 7:30 am
GNW
Active Biotech to Present at the 33rd Annual J.P. Morgan Healthcare Conference
29 Dec 2014 2:30 pm
GNW
Active Biotech's rights issue of approximately ...
09 Dec 2014 7:30 am
GNW
Active Biotech's election committee appointed
05 Dec 2014 7:30 am
GNW
Prospectus relating to Active Biotech's rights ...
 
Headlines
Top categories
Company finder

a d v e r t i s e m e n t